Medscape Conference Coverage, based on selected sessions at the:

American Society of Hematology (ASH) 50th Annual Meeting and Exposition

December 06 - 09, 2008; San Francisco, California

This activity is not sanctioned by, nor a part of, the American Society of Hematology. Conference news does not receive grant support and is produced independently.

Conference News

  • Anticoagulants: A New Therapy for Cancer?

    Growing evidence, both experimental and clinical, shows that anticoagulants, and particularly low-molecular-weight heparin, may play an important role in cancer treatment.
    Medscape Medical News, December 22, 2008
  • Cultured Cord Blood Optimizes Engraftment

    Cord blood that is cultured before transplantation greatly increased the number of CD34 progenitor cells and decreased the time to engraftment in patients with acute myeloid leukemia.
    Medscape Medical News, December 17, 2008
  • Combination Therapy Shows Promise in AML

    Combining the experimental agent AS1411 with high-dose cytarabine appeared to be well tolerated and showed signs of efficacy in patients with relapsed and refractory acute myeloid leukemia (AML).
    Medscape Medical News, December 17, 2008
  • Cord Blood for Adult Stem-Cell Transplants

    In the absence of an HLA-matched sibling donor, partially matched cord blood with an adequate cell dose is a suitable alternative for the large proportion of patients who lack an 8-of-8-matched unrelated adult donor, or if transplantation is urgent.
    Medscape Medical News, December 14, 2008
  • Pralatrexate and Peripheral T-Cell Lymphoma

    The investigational agent pralatrexate produced complete and partial responses in patients with refractory or relapsed peripheral T-cell lymphoma, and might provide a novel platform for future treatment regimens.
    Medscape Medical News, December 12, 2008
  • Older Age and Allogeneic Stem-Cell Transplant

    Outcomes in patients 65 years and older undergoing allogeneic stem-cell transplantation for the treatment of acute myeloid leukemia and myelodysplastic syndromes are similar to those in younger adults, even after adjustment for multiple risk factors.
    Medscape Medical News, December 11, 2008
  • ASH 2008: New Data Confirm Increased Mortality With ESAs in Cancer Patients

    A new meta-analysis of individual patient data have confirmed the increased risk for death in cancer patients receiving erythropoietin-stimulating agents.
    Medscape Medical News, December 10, 2008
  • ASH 2008: Eltrombopag Offers "Important New Option" in ITP

    The just-approved drug produces responses in patients with idiopathic thrombocytopenic purpura who are refractory to other treatments.
    Medscape Medical News, December 10, 2008
  • Dexamethasone Reduces Relapse Rate

    When used in induction, dexamethasone is more effective than prednisone in reducing relapse in pediatric patients with acute lymphoblastic leukemia. However, there are no differences in long-term survival.
    Medscape Medical News, December 9, 2008
  • Therapeutic vs Prophylactic Platelet Transfusions

    Treating cancer patients who become thrombocytopenic with platelet infusions only when they bleed, rather than prophylactically, is safe, feasible, and could reduce costs considerably, say German researchers.
    Medscape Medical News, December 9, 2008
  • Imatinib Can Be Discontinued in CML Patients

    Imatinib therapy can be discontinued in patients with chronic myeloid leukemia who experience a complete molecular response; it does not automatically lead to relapse.
    Medscape Medical News, December 8, 2008
  • Addition of Rituximab Doubles Response in ITP

    Rituximab added to dexamethasone doubles the response rate, compared with dexamethasone alone, in idiopathic thrombocytopenic purpura.
    Medscape Medical News, December 7, 2008
  • New Therapy for B Cell Non-Hodgkin's Lymphoma

    Fostamatinib disodium, an oral investigational treatment that targets spleen tyrosine kinase, demonstrated tumor response among patients with relapsed or refractory B cell non-Hodgkin's lymphoma.
    Medscape Medical News, December 7, 2008
  • Prophylaxis Halves Thromboembolic Events

    Cancer patients receiving chemotherapy who took nadroparin showed a 50% reduction in thromboembolic events in the PROTECHT study.
    Medscape Medical News, December 7, 2008
  • Dose of Platelet Transfusions Can Be Halved

    The dose of platelets given by transfusion to cancer patients who become thrombocytopenic can be halved without increasing the risk of bleeding, say researchers presenting the PLADO study.
    Medscape Medical News, December 6, 2008
  • Hot Research to Be Presented at ASH 2008

    Results from several phase 3 trials will be presented at the upcoming meeting of the American Society of Hematology.
    Medscape Medical News, December 2, 2008

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Hematology. These materials and the related activity are not sanctioned by the American Society of Hematology or any commercial supporters of the conference and do not constitute an official part of that conference.